Molecular structure of Dabrafenib, CAS Number: 1195765-45-7
Dabrafenib (CAS 1195765-45-7)
See product citations (6)
Alternate Names:
GSK2118436A
Application:
Dabrafenib is a potent and selective inhibitor of Raf-B protein kinase carrying V600E mutation
CAS Number:
1195765-45-7
Molecular Weight:
519.56
Molecular Formula:
C23H20F3N5O2S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Dabrafenib is a compound extensively researched in the context of its interaction with specific enzymes in signal transduction pathways. It is primarily used as a tool to study the mitogen-activated protein kinase (MAPK) pathway, which is involved in the regulation of cell proliferation and survival. By inhibiting particular kinases within this pathway, Dabrafenib helps researchers to understand the intricate processes of intracellular signaling and the consequences of kinase dysregulation. In molecular biology, the compound is utilized to investigate the effects of kinase inhibition on gene expression and the phenotypic outcomes in cellular models. Additionally, Dabrafenib serves as a reference substance to explore the specificity and selectivity of kinase inhibitors and to develop assays that can measure enzyme inhibition in vitro.
Dabrafenib (CAS 1195765-45-7) References
- Dabrafenib Effective in Pediatric Glioma. | . 2017. Cancer Discov. 7: OF5. PMID: 28062673
- Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. | Phadke, M., et al. 2018. Mol Oncol. 12: 74-88. PMID: 29112787
- Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. | Salama, AKS., et al. 2020. J Clin Oncol. 38: 3895-3904. PMID: 32758030
- Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry. | Balakirouchenane, D., et al. 2021. J Pharm Biomed Anal. 193: 113718. PMID: 33166838
- Dabrafenib Promotes Schwann Cell Differentiation by Inhibition of the MEK-ERK Pathway. | Park, K., et al. 2021. Molecules. 26: PMID: 33917810
- Inhibition of human UDP-glucuronosyltransferase enzyme by Dabrafenib: Implications for drug-drug interactions. | Yin, H., et al. 2021. Biomed Chromatogr. 35: e5205. PMID: 34192355
- The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension. | Meijles, DN., et al. 2021. Clin Sci (Lond). 135: 1631-1647. PMID: 34296750
- Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease. | Uday, RVS., et al. 2021. PLoS One. 16: e0257206. PMID: 34506566
- Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor. | Grenier-Chartrand, F., et al. 2022. Acta Neurochir (Wien). 164: 737-742. PMID: 35029761
- Dabrafenib- and trametinib-associated glomerular toxicity: A case report. | Jo, E. and Rhee, H. 2022. Medicine (Baltimore). 101: e28485. PMID: 35029901
- Prediction of Drug-Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation. | Wang, Z., et al. 2022. Eur J Drug Metab Pharmacokinet. 47: 353-361. PMID: 35147853
- Erdheim-Chester Disease Successfully Treated with Front-Line Single-Agent Dabrafenib. | Salama, H., et al. 2022. Am J Case Rep. 23: e935090. PMID: 35171900
- Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance. | Ernst, T., et al. 2022. BMJ Case Rep. 15: PMID: 35396243
- Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL). | González-Barrallo, I., et al. 2022. Melanoma Res. 32: 343-352. PMID: 35762583
- First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma. | Kim, CG., et al. 2022. J Am Acad Dermatol. 87: 989-996. PMID: 36068115
Inhibitor of:
2700090O03Rik, 7420461P10Rik, BBS8, Brk, C20orf160, CNKSR3, DAN, FAM149B1, Gm3696, Gm9766, gp100, GPR172C, HACE1, KIAA1549, LIN-45, MAGE-C3, Melan-A, Melanoma Marker, Mos, Olfr209, Olr1064, Olr1156, Olr1204, Olr1235, Olr1350, Olr1404, Olr1564, Olr180, Olr309, Olr357, Olr363, Olr496, Olr532, Olr592, Olr607, Olr608, Olr697, Olr724, Olr736, Olr768, Olr773, Olr838, Olr889, Olr962, Olr964, podoplanin, Raf-1, raf-A, Raf-B, RASAL1, RASSF1, RBMY1A, RGL1, RICK, RIP5, RIPK, RKIP, RREB1, RSPRY1, Ser/Thr Protein Kinase, SNFT, SPRED1, SS18L2, T3JAM, TFIIH p62, Tmem217, and TREM-2b.Activator of:
BXDC2, Melanoma, MFAP3L, raf-A, and RAO.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dabrafenib, 5 mg | sc-364477 | 5 mg | $138.00 | |||
Dabrafenib, 25 mg | sc-364477A | 25 mg | $255.00 | |||
Dabrafenib, 50 mg | sc-364477B | 50 mg | $273.00 | |||
Dabrafenib, 100 mg | sc-364477C | 100 mg | $403.00 | |||
Dabrafenib, 10 g | sc-364477D | 10 g | $12240.00 |